

ALT/GPT (UV) **Kinetic-IFCC Method**



PRODUCT CODE CZ003

INTENDED USE

This reagent is intended for in vitro quantitative determination of ALT/GPT in serum or plasma.

CLINICAL SIGNIFICANCE

Alanine Aminotransferase (ALT or GPT) is present in high concentrations in the liver and to a lesser extent in kidney, heart and skeletal muscle, pancreas, spleen and lung. Increased levels of ALT however are generally a result of liver disease associated with some degree of hepatic necrosis such as cirrhosis, carcinoma, viral or toxic hepatitis and obstructive jaundice. Characteristically ALT is generally higher than AST in acute viral or toxic hepatitis, whereas for most patients with chronic hepatic disease, ALT levels are generally lower than AST levels. Elevated ALT levels have also been found in extensive trauma and muscle disease, circulatory failure with shock, hypoxia, myocardial infarction and haemolytic disease. PRINCIPLE

The amino group is enzymatically transferred by ALT present in the sample from alanine to the carbon atom of 2-oxoglutarate yielding pyruvate and L-glutamate. Pyruvate is reduced to lactate by LDH present in the reagent with the simultaneous oxidation of NADH to NAD+. The reaction is monitored by measuring the rate of decrease in absorbance at 340nm due to the oxidation of NADH. ALT/GPT

LDH Pyruvate + NADH+ H⁺ ____ D-Lactate +NAD⁺

REAGENT COMPOSITION

REAGENT	1 (enzyme reagent)
m: 1176	

Tris pH 7.5	100 mmol/L
L-Alanine	500 mmol/L
LDH	\geq 1200 u/L
REAGENT 2 (substrate)	
2-Oxoglutarate	15 mmol/L
NADH	0.18 mmol/L

REAGENT PREPARATION SUBSTRATE START

R1 and R2 are ready-to-use and stable upto the expiry date if contamination is avoided and stored at 2-8°C and protect from light.

SAMPLE START

Mix 4 parts of R1 + 1 Part of R2 = Mono reagent Stability of mono reagent: 4 Weeks at 2-8°C, 4 days at 15-25°C Protect from light. **Note:** Discard the working reagent if the blank absorbance less than 1.0 at 340 nm

Bio Research For Medical Diagnostics Muslim Al Attar Street, P.O.Box:1235, Amman-11953.Jordan Tel:+962 64892525, Fax: +962 64892526

www.bioresearch.com.jo

SPECIMEN

Serum, heparinized plasma

PRECAUTION

- 1- The reagents contain sodium azide as preservative. Do not swallow and avoid contact with skin and mucous membranes.
- 2-To avoid contamination, use clean laboratory wares. Avoid direct exposure of reagent to light.

ASSAY

Wavelength	:	340 nm, Hg 365 nm, Hg 334 nm
Cuvette	:	1 cm light path
Temperature	:	25°C/ 30°C/37°C
A 11 A 1		· · · · · · · · ·

Adjust the instrument to zero with distilled water or air

PROCEDURE SUDETDATE STADT

Temperature→	25°C or 30°C	37°C		
Reagent 1 Buffer	1000 uI	1000 µI		
Keagent I Dunei	1000 μL	1000 µL		
Sample	200 µL	100 µL		
Mix incubates for approx 1 min, then add,				
Reagent 2 Substrates	250 μL	250 µL		

SAMPLE START

Mono reagent (R1+R2)	1000 μL	1000 µL
Sample	200 µL	100 µL

READING FOR BOTH

Mix and read absorbance after 1 min and start stop watch. Read absorbance again after 1, 2 and 3 min.

CALCULATION

Multiply factor from ta	ble below with $\Delta A/min$,	
Substrate start	25°C / 30°C	<u>37°C</u>
340 nm	1151	2143
334 nm	1173	2184
365 nm	2132	3971
Sample start	<u>25°C / 30°C</u>	<u>37°C</u>
340 nm	952	1745
334 nm	971	1780
365 nm	1765	3235

LINEARITY

up to 400 U/L, the sample should be diluted 1 + 9 with 0.9 % NaCl solution, if ΔA /min exceeds 0.16 at 340 nm or 334 nm, or 0.08 at 365 nm. Multiply the result by 10.



MDSS GmbH Schiffgraben 41 30175 Hannover, Germany

NORMAL RANGE

	25°C	30°C	37°C
Men up to	22 U/L	30 U/L	42 U/L
Women up to	17 U/L	23 U/L	32 U/L
Each laboratory should	establish reference	ranges for	ite own

Each laboratory should establish reference ranges for its own patients' population.

OUALITY CONTROL

All control sera with values determined by this method can be used.

SYMBOL ON LABELS

Symbols	Signify	Symbols	Signify
REF	Catalogue Number	SIZE	Pack Size
	Expiry Date	VOL	Volume
K	Storage Condition	LOT	Lot Number
Ĩ	Instruction for Use	IVD	In Vitro Diagnostics
	Manufacturing Date	••••	Manufacturer
$\overline{\Sigma}$	Number of Tests	2	For Single Use Only
EC REP	EC Representative	CE	European conformity

BIBILOGRAPHY

- 1- Clin. Chem. ACTA 105 (1980) S. 147-172 Synopsis Der Leberkrankheiten : H. Wallhofer, E. Schmidt.
- 2- .Thefeld W. ET. AI. DT . MED. WSCHR. 99 (1974) 343.

Doc.No.: IFU-CH-003 Rev.: 06 Page 1 of 1